A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

NCT05984277 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

1200

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Non-small Cell Lung Cancer

Interventions

DRUG: Volrustomig
DRUG: Pembrolizumab
DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: Pemetrexed

Sponsor

AstraZeneca